Thus, for patients with refractory advanced prostate cancer who have failed androgen deprivation therapy, androgen receptor signaling inhibitors, and docetaxel, the exploration of new targets against MRGs could provide new perspectives on the underlying mechanisms of prostate cancer and ultimately contribute to a broader understanding of this complex disease [26,27,28]. This evidence concerns the gene AR and prostate cancer.